NextCure, Inc. NXTC · Stock Open NextCure, Inc. in new tab
NextCure, Inc. Analysis (NXTC)
Is NextCure, Inc. a good investment? NextCure, Inc. (NXTC) is currently trading at 5.46 USD.
Earnings Schedule: NextCure, Inc. is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -5.90.
Investor FAQ
Does NextCure, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is NextCure, Inc.?
NextCure, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -8.28.
Company Profile
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company's product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer's disease; and NC605 an antibody that targets Siglec-15, as well as chronic bone diseases, such as osteoarthritis and non-union fractures. The company also develop SIM0505, a novel antibody-drug conjugate (ADC) targeting CDH6 (cadherin-6 or K-cadherin) for the treatment of solid tumors. The company was incorporated in 2015 and is headquartered in Baltimore, Maryland.
| Split Date | Split Ratio to 1 |
|---|---|
| July 14, 2025 | 1:12 |
Community Discussion